Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam.

ABSTRACT:

Aims

We investigated savolitinib pharmacokinetics (PK) when administered alone or in combination with rifampicin, itraconazole or famotidine, and investigated midazolam PK when administered with or without savolitinib in healthy males.

Methods

Savolitinib PK was evaluated before/after: rifampicin (600 mg once daily [QD] for 5 days); itraconazole (200 mg QD for 5 days); a single dose of famotidine (40 mg QD) 2 hours before savolitinib. Midazolam PK was evaluated before/after midazolam (1 mg QD) with or without savolitinib (600 mg QD). Each study enrolled 20, 16, 16 and 14 volunteers, respectively. Plasma samples were collected to determine the effect on PK.

Results

The geometric mean ratios (GMR, %) (90% confidence intervals [CIs]) for savolitinib alone and in combinat

SUBMITTER: Ren S 

PROVIDER: S-EPMC9292161 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature